We profiled 77 nonesmall-cell lung cancer patients with paired baseline and progression blood samples treated with the third-generation EGFR tyrosine kinase inhibitor (TKI) rociletinib using a broad cell-free circulating DNA (cfDNA) next-generation sequencing (NGS) gene panel. We demonstrated a utility of cfDNA NGS to detect EGFR T790M and predict response comparable to tissue-based tests, even at low allele fractions, and we identified resistance mechanisms. Our findings highlight the genomic heterogeneity observed in disease after progression while receiving therapy with a third-generation EGFR TKI. Introduction: The genomic alterations driving resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) are not well established, and collecting tissue biopsy samples poses potential complications from invasive procedures. Cell-free circulating DNA (cfDNA) testing provides a noninvasive approach to identify potentially targetable mechanisms of resistance. Here we utilized a 70-gene cfDNA next-generation sequencing test to interrogate pretreatment and progression samples from 77 EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with a third-generation EGFR TKI. Patients and Methods: Rociletinib was evaluated in advanced or metastatic (second line or higher) disease with EGFR T790M-positive NSCLC in the TIGER-X (NCT01526928) and TIGER-2 (NCT02147990) studies. Plasma samples were collected at baseline and at the time of systemic progression while receiving rociletinib. The critical exons in 70 genes were sequenced in cfDNA isolated from plasma samples to elucidate a comprehensive genomic profile of alterations for each patient. Results: Plasma-based cfDNA analysis identified 93% of the initial EGFR activating and 85% of the EGFR T790M resistance mutations in pretreatment samples with detectable tumor DNA. Profiling of progression samples revealed significant heterogeneity, with different variant types (eg, mutations, amplifications, and fusions) detected in multiple genes (EGFR, MET, RB1) that may be driving resistance in patients. Novel alterations not previously described in association with resistance to third-generation TKIs were also detected, such as an NTRK1 fusion. Conclusion: cfDNA next-generation sequencing identified initial EGFR activating and secondary T790M resistance mutations in NSCLC patients with high sensitivity, predicted treatment response equivalent to tissue analysis, and identified multiple novel and established resistance alterations.
Introduction
Robust and durable responses have been observed in non-small cell lung cancer (NSCLC) patients with EGFR activating mutations treated with first-and second-generation EGFR tyrosine kinase inhibitors (TKIs). [1] [2] [3] [4] EGFR genotyping is now standard practice in advanced NSCLC, and the prevalence of EGFR activating mutations ranges from approximately 15% in white to 40% in Asian populations. 5 These patients, however, almost inevitably experience disease progression in 10 to 14 months. 6 Acquired resistance mechanisms to the first-and second-generation EGFR TKIs erlotinib, gefitinib, and afatinib have been well described, with the EGFR T790M mutation driving resistance in at least half of patients. [7] [8] [9] The activation of bypass pathways has also been observed as a potential mechanism of resistance to EGFR TKIs, and involves multiple pathways of at least 4 different types of alterations in multiple genes, including focal copy number amplifications in MET, ERBB2 (HER2), or ERBB3; missense mutations in BRAF, MAP2K1 (MEK1), PIK3CA, or KRAS; inactivating mutations or allelic loss in PTEN or RB1 (the latter a hallmark of epithelial-mesenchymal transition to a small-cell phenotype), and fusions in ALK.
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The third-generation EGFR TKIs osimertinib and rociletinib inhibit both EGFR activating and T790M mutations, and have demonstrated activity in NSCLC patients with disease that progressed while receiving therapy with first-or second-generation EGFR inhibitors. 6, [10] [11] [12] In 2015, osimertinib was approved for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease had progressed while receiving or after receiving EGFR TKI therapy. 13 Although third-generation EGFR TKIs have shown robust and durable responses in patients, acquired resistance invariably develops, and the mechanisms of resistance to third-generation TKIs are less well described. In a previous report, profiling of cell-free circulating DNA (cfDNA) and tissue biopsy samples collected at the time of progression while receiving rociletinib demonstrated an increase in EGFR T790M in 6 of 12 patients evaluated; however, T790M was not detectable in the remaining patients, suggesting alternative mechanisms of acquired resistance.
14 None of the patients developed an EGFR C797S mutation, which has been reported to drive progression in one third of patients receiving osimertinib, 15 and less commonly rociletinib. 16 An epithelialemesenchymal transition to a small-cell lung cancer phenotype was observed in 2 patients, with one driven by an RB1 inactivating mutation and another with allelic loss of RB1, while 3 patients exhibited EGFR amplification. 14 These findings were similar in another case series of 4 patients who underwent biopsy after disease progression while receiving osimertinib, with one patient exhibiting small-cell transformation and RB1 loss of function, one with FGFR1 amplification, and one with increased EGFR ligand expression. 17 In 7 patients who underwent biopsy after disease progression on either rociletinib or osimertinib, MET and/or ERBB2 (HER2) amplifications were found with fluorescence in-situ hybridization, while targeted sequencing found an acquired KRAS G12S as EGFR T790M became undetectable. 18 Potential targeting of these resistance alterations acquired while receiving third-generation TKIs has been suggested by case reports of combined osimertinib and crizotinib treatment response of a MET amplification after confirmed osimertinib response in a EGFR T790M-positive patient; 19 and also of an EML4-ALK fusion found in the plasma of a patient with disease progression while receiving osimertinib. 20 To date, the largest report investigating resistance in EGFR T790M patients with a cfDNA targeted next-generation sequencing (NGS) panel was a 43-patient study evaluating patients whose disease progressed while receiving rociletinib. 16 A low frequency (2.3%) of EGFR C797S alterations was observed; however, 65% of the patients had alterations potentially responsible for acquired resistance, including MET, ERBB2, and EGFR amplifications; missense mutations in PIK3CA, EGFR, KRAS, and CDKN2A; and at lower prevalences alterations in RB1, ALK, KIT, and MET.
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Taken together, these studies suggest that resistance to thirdgeneration TKIs is driven by multiple genes and different types of genomic alterations.
Here we expand on previous smaller series that used cfDNA NGS to understand mechanisms of acquired resistance to thirdgeneration EGFR TKIs from banked paired samples. Although rociletinib is no longer being developed for use in NSCLC, the TIGER-X and TIGER-2 studies can be used to validate the utility of cfDNA NGS to predict response and to understand mechanisms of resistance to third-generation EGFR TKIs. In particular, one key unanswered question is whether plasma-detected EGFR T790M variants at very low allele fractions still predict TKI response. The TIGER-X/2 studies evaluated rociletinib in patients receiving second-line or later therapy with tissue-positive EGFR T790M NSCLC. Pretreatment and progression plasma samples from 77 T790M tissue-positive cases treated with rociletinib were analyzed by a targeted cfDNA assay sequencing the complete exons of 30 genes and the critical exons in 40 genes, and detecting all 4 major types of genomic alterations: single nucleotide variants and short insertions/deletions (indels) in 70 genes, copy number amplifications in 16 genes, and fusions in 6 genes. 21 Significant genomic heterogeneity, both in terms of genes and variant types, was observed in these samples after acquired resistance to rociletinib. Serial testing of selected cases was further analyzed to understand the temporal emergence of resistance mechanisms.
Patients and Methods

Study Design
Patients evaluated were enrolled onto the TIGER-X (NCT01526928) or TIGER-2 (NCT02147990) studies, which evaluated the safety and efficacy of rociletinib (CO-1686) in secondline or later EGFR T790M-positive or T790M-negative NSCLC patients. Patients received oral rociletinib (500 or 625 mg 2 times a day) in 21-day continuous cycles until disease progression according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, unacceptable toxicity, or withdrawal of consent. In this analysis, RECIST responses and the change from baseline in the sum of the target lesions were assessed by the investigators. Treatment beyond progression was permitted if the investigator believed the patient was still benefiting from rociletinib therapy. Plasma samples were collected from all patients at screening and at every cycle of treatment; however, the subcohort for this study was limited to those patients for whom paired banked baseline and at progression samples were still available. The visit cutoff date was September 18, 2015, and included patients enrolled onto the TIGER-X or TIGER-2 studies as of July 1, 2015. The study protocols were approved by the institutional review board at participating centers, and all patients provided informed consent before treatment.
EGFR Assessment by Tissue
DNA was extracted from two 5 mm sections, and central laboratory tissue testing was performed with the Therascreen EGFR RGQ PCR Kit (Qiagen, Germantown, MD). Additional details regarding sample collection and processing have been described elsewhere. 22 
Plasma Sample Collection and Processing
Blood samples were collected in K 2 EDTA tubes (up to four 6 mL Vacuettes), processed into plasma within 30 minutes (1800 Â g for 10 minutes at 18-23 C) , and stored at -70 C or below before processing. DNA extraction was performed from 1 to 2 mL as described previously 23 and was quantified using a Qubit fluorometer. For BEAMing, DNA was extracted using the QIAamp DNA Circulating Nucleic Acid Kit according to the manufacturer's instructions.
cfDNA NGS
DNA was sequenced utilizing a targeted 70-gene panel (Supplemental Table 1 in the online version) on an Illumina HiSeq 2500 platform at a Clinical Laboratory Improvement Amendmentsecertified, College of American Pathologistsaccredited, New York State Department of Healtheapproved laboratory (Guardant Health, Redwood City, CA). This cfDNA NGS test uses hybrid capture and molecular barcoding in a method known as digital sequencing to sequence the critical exons in 70 genes, and includes all 4 major types of alterations: single nucleotide variants, indels, selected copy number amplifications, and fusions. 21 The sensitivity and specificity of this test have previously been described. [23] [24] [25] The fractional concentration or variant allele frequency (VAF) for a given mutation was calculated as the fraction of circulating tumor DNA harboring that mutation in a background of wild-type cfDNA fragments. Somatic alterations are differentiated from germline variants in cfDNA by taking into account VAF distributions as well as prior evidence in large population and somatic database, such as ExAC, COSMIC, and internal databases. Plasma copy number amplification is determined using the normalized ratio of DNA fragments for a given gene compared to a panelwide baseline. Samples were considered positive for circulating tumor DNA (ctDNA) if at least one somatic alteration was detected.
BEAMing
DNA was preamplified and then used to perform single-molecule PCR on magnetic beads in water-in-oil emulsions. Beads with mutant products were distinguished from wild type by using allelespecific, fluorescently labeled probes, and the bead populations were counted by flow cytometry. Primers and probes were designed to interrogate the T790M and L858R substitution mutations in EGFR, as well as several of the most common deletions in exon 19. The total number of genome equivalents of DNA isolated from plasma was quantified with a modified LINE-1 quantitative realtime PCR assay, as described previously. 26 Mutant plasma copy numbers were obtained by multiplying the percentage of mutant beads by the number of genome equivalents.
Statistical Analysis
All statistical analysis was performed by GraphPad Prism, R basic, stats, dplyr, and ComplexHeatmap software packages.
Results
Patient Characteristics
The TIGER-X 11, 12 and TIGER-2 studies evaluated rociletinib in second-line or later NSCLC patients with or without EGFR T790M mutations. Patients who experienced systemic disease progression while receiving rociletinib were selected for cfDNA profiling on the basis of the availability of baseline and progression plasma samples (n ¼ 77). Only patients who were EGFR T790M-positive in a pretreatment tumor biopsy utilizing the US Food and Drug Administration approved Therascreen EGFR RGQ PCR assay were included in this analysis. Demographic characteristics were typical of patients with EGFR-mutated NSCLC (Supplemental Table 2 in the online version). The median number of prior therapies was 2 (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] , and the median number of prior TKIs was 1 (range, 1-4). Erlotinib was the most frequent type of previous EGFR TKI (92.2% of patients received prior treatment with erlotinib).
EGFR Mutation Status at Baseline
Somatic alterations were detected in 96% (74/77) of the pretreatment plasma samples with cfDNA NGS. In these 74 samples with detectable somatic alterations (ctDNA positive), the range of cfDNA isolated was 8.1 to 731 ng/mL, with a median of 91 ng/ mL. Known EGFR activating mutations (L858R, Ex19Del, and G719X) and the acquired resistance mutation EGFR T790M were identified by NGS in 93% (69/74) and 85% (63/74) of ctDNA-positive pretreatment samples, respectively ( Figure 1A ). The VAF of EGFR activating and T790M mutations ranged from 0.05% to 96.8% and 0.10% to 45.4%, with a median of 6.71% and 3.34%, respectively. The allele fraction of T790M was frequently lower than that of EGFR activating L858R, Ex19Del, and G719X (Wilcoxon P ¼ .015), suggesting that the T790M alteration was subclonal ( Figure 1B ). Compound EGFR-activating mutations including L858R, Ex19Del, and G719X, and one or more EGFR comutations (eg, E709A/K, L718V, T725M, S768I, and K860I) were observed in 12% (9/74) of pretreatment samples with activating mutations (Supplemental Figure 1 in the online version).
Pretreatment EGFR mutation allele fractions for L858R, Ex19Del, and T790M were also determined for 76 samples by BEAMing, an orthogonal technique based on droplet digital PCR followed by flow cytometry (Supplemental Figure 2 in the online version). 27, 28 All of the samples analyzed by NGS and BEAMing were collected within 14 days of each other. The EGFR T790M alteration was detected in 59 samples using both assays; however, 4 samples were each identified using one assay but not the other. There was perfect concordance (16/16) in plasma samples where EGFR L858R was detected, whereas EGFR exon 19 deletions were detected in more pre-rociletinib plasma samples (n ¼ 50) using 
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Comprehensive Genomic Profiling of Baseline Specimens
Plasma sequencing of 74 ctDNA-positive baseline samples revealed significant heterogeneity in this population of patients receiving second-line and later therapy after disease progression while receiving an EGFR-directed therapy. Across genes targeted in the broad cfDNA panel, somatic mutations were detected at VAFs ranging from 0.03% to 97%, with a median of 1.39% (Supplemental Figure 3 in the online version). An oncoprint plot of ctDNA profiled from 73 patients was generated for the 15 genes reported to be most frequently mutated in NSCLC in The Cancer Genome Atlas data set and included in the targeted gene panel ( Figure 1C ). 29 Consistent with The Cancer Genome Atlas data set, the most frequent genomic alterations overall outside of EGFR were TP53 (63%), PIK3CA (18%), MET (15%), and RB1 (15%). The most common amplifications were seen in EGFR (46%), MET (13.5%), and PIK3CA (12%); however, these included chromosomal aneuploidy events. Removing likely aneuploid amplification events where several genes on the panel (BRAF, CDK6, EGFR) colocated with MET on chromosome 7 were amplified left only one sample with a focal MET amplification.
Baseline EGFR Mutations and Clinical Outcomes Analysis
Upon treatment with rociletinib, 84% (66/77) patients showed no change or a decrease from before treatment in the sum of the longest diameter of target lesions (SLD), with a median reduction of 38.4%, whereas 11 patients showed an increase in SLD ( Figure 2A ). The confirmed objective response rate (ORR) was similar in patients who were T790M positive by tissue analysis (29.9%; 95% confidence interval [CI], 20.0-41.4; n ¼ 77) compared to patients who were T790M positive by plasma analysis (28.6%; 95% CI, 17.9-41.3; n ¼ 63). Similarly, the median progression-free survival (PFS) was almost identical in patients who were T790M positive by tissue analysis (median, 4.2 months; 95% CI, 3.9-5.7; range, 0.8-18.6 months; n ¼ 77) or T790M positive by plasma analysis (median 4.1 months; 95% CI, 3.9-5.6; range, 0.8-12.9 months; n ¼ 63; Figure 2B ). No significant difference was observed in the duration of response in patients who were T790M positive by tissue analysis (median, 4.8 months; 95% CI, 3.7-6.7 months; range, 2.7-16.6 months; n ¼ 23) compared to patients who were T790M positive by plasma analysis (median, 4.8 months; 95% CI, 2.8-6.7 months; range, 2.7-11.1 months; n ¼ 18; Supplemental Figure 4 in the online version). Importantly, neither the absolute plasma VAF of T790M nor the ratio of T790M to EGFR activating mutation before treatment correlated with the percentage change in SLD (r ¼ 0.19 and 0.008, respectively; Figure 2C ). These results suggest that tissue and plasma cfDNA profiling both effectively capture patients likely to benefit from rociletinib treatment.
EGFR Mutation Status at Progression
Somatic alterations in cfDNA were detected in 99% (76/77) of plasma samples collected from patients who experienced progression while receiving rociletinib treatment. EGFR activating and T790M mutations were identified in 74% (56/76) and 50% (38/76) of ctDNA-positive progression samples, respectively ( Figure 3A) . Notably, 22% (11/50) of Ex19Del and 7% (1/15) of L858R mutations became undetectable in plasma profiled at progression. Patients with an increase in SLD at the first scan performed at 6 to 8 weeks were defined as having innate resistance, and those with acquired resistance had a decrease in SLD followed by an increase. Of patients who retained the EGFR activating mutation at progression, all 9 of the patients with innate resistance retained the T790M mutation in their ctDNA, whereas T790M decreased to an undetectable level in 39% (18/46) of the patients with acquired resistance. The median VAF of the activating mutation was significantly higher in T790M-negative samples (median, 8.2%; range, 0.36-93.5%) than T790M-positive samples (median, 1.8%; range, 0.14-43%; P ¼ .017). In addition, the ratio of T790M to activating VAF for T790M-positive samples decreased significantly from pretreatment samples to progression samples (P ¼ .0033; Figure 3B ), suggesting that rociletinib selectively reduced tumor clones containing the T790M variant.
Mechanisms of Acquired Resistance to Rociletinib
A wide array of variants either increased or emerged after disease progression while receiving rociletinib therapy. The alterations that were detected included single nucleotide variants, indels, copy number amplifications, and fusions in multiple genes. In 14% (11/65) of patients with acquired resistance and ctDNA-positive plasma, mutations in genes involved in the RAS/RAF signaling pathway, including KRAS Q61H, KRAS K117N, HRAS G12R, and NRAS G10R, increased in VAF or emerged at progression ( Figure 3C ). These and other acquired resistance pathways are illustrated in the oncoprint plot in Figure 3D . Acquired RAS mutations, as well as BRAF and MAP2K2 (MEK2) mutations, co-occur with EGFR mutation in this EGFR-mutated cohort ( Figure 3D ), but they did not co-occur with EGFR in the baseline samples ( Figure 1C ). In addition to the mitogen-activated protein kinase (MAPK) pathway, recurrent mutations associated with EGFR TKI resistance were also found in signaling components of the phosphatidylinositol 3-kinase pathway (PIK3CA, PTEN, TSC1). The comutation plot also illustrates examples of convergent evolution where the same resistance mechanism was found in multiple patients; for example, EGFR C797S, PIK3CA E545K, and focal MET amplification were each seen in 3 of 65 patients with acquired resistance. Additional emergent variants that were detected but that are not typically associated with EGFR TKI resistance included a TPM3-NTRK1 fusion, several truncating mutations in ARID1A, and frameshift indels in NF1. Patient vignettes with some of the emergent alterations that were detected are discussed in the paragraphs that follow.
EGFR C797S Acquired Resistance
EGFR C797S has been observed as a mechanism of resistance to rociletinib and osimertinib in patients. 15, 16 An EGFR C797S variant was detected in 4.5% (3/66) of patients with acquired resistance to rociletinib with VAF of 0.07%, 0.14%, and 0.84% ( Figure 4A ). The activating mutations for these 3 patients were Ex19Del, which were still maintained along with T790M. Notably, all 3 patients with C797S initially had a partial response; however, systemic progression occurred after 185 to 358 days of rociletinib 
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treatment. The emerging C797S alteration was first detected 45 to 49 weeks after the initiation of rociletinib treatment and likely drove resistance to rociletinib. These results suggest that the emergence of C797S may result from exposure to third-generation TKIs.
KRAS Alteration Acquired Resistance
Another patient experienced a partial response to rociletinib on day 41 of treatment ( Figure 4B and C) and experienced disease progression on day 118 with the emergence of a new brain lesion ( Figure 4D ). The patient continued to benefit from rociletinib treatment and continued to receive therapy until systemic progression due to a new lesion in the neck occurred on day 297 (data not shown). Profiling of ctDNA showed an initial reduction of both the EGFR activating and T790M alteration coincident with the initial clinical response; however, an emergent KRAS Q61H mutation was observed at the time of systemic progression ( Figure 4B ). This mutation has been reported to drive resistance to first-and secondgeneration EGFR TKIs in colorectal and lung adenocarcinoma, 30 and it has previously been detected in rociletinib-and osimertinib-treated patients. 16, 18 The KRAS Q61H mutation was first detected at day 191 after treatment at a VAF of 0.67% and increased to 5.7% by day 297, comparable to the VAF of the activating EGFR Ex19Del alteration (5.4%). The emergence of a NF1 nonsense Q1577* mutation at 2.2% VAF was also observed on day 191 and maintained at day 297 (0.67% VAF).
NTRK1 Fusion Acquired Resistance
One patient had stable disease for 168 days while receiving rociletinib treatment ( Figure 5A and B) until she experienced systemic progression on day 229 due to an increase in target lesions ( Figure 5A and B) . The patient continued receiving rociletinib treatment until she died on day 258 of disease progression. 
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A truncating germline BRCA1 E23fs (frameshift) alteration was detected in baseline plasma, and across all longitudinal cfDNA samples, from this patient ( Figure 5A ). Truncating germline BRCA1 I2315fs and somatic BRCA2 N3337fs alterations were also observed in the baseline cfDNA of 2 additional patients (data not shown). Before rociletinib treatment, compound EGFR G719C-S768I, NF1 F1397fs, CTNNB1 D32N, and SMAD4 Q446fs variants were detected at low levels (VAF ranging from 0.1% to 0.5%). The T790M resistance alteration was detected at a low level (0.16%) in the baseline sample; however, it was not detected in the progression sample despite a VAF of 21% for the EGFR activating mutation G719C. At day 223 (6 days before disease progression by imaging), a TPM3-NTRK1 fusion emerged in plasma cfDNA at 0.14% VAF and continued to increase to 10% on day 258. Concurrently, the compound EGFR mutations (G719C and S768I) as well as the SMAD4 Q446fs and CTNNB1 D32N variants increased up to a VAF of 68%. Amplification of EGFR, FGFR1, MYC, and PIK3CA were also observed at progression; however, only MYC was confirmed to have focal amplification (data not shown). Thus, comprehensive plasma profiling revealed significant heterogeneity and the activation of multiple bypass pathways resulting from concurrent alterations in EGFR, NTRK1, SMAD4, CTNNB1, and MYC ( Figure 5C ).
MET Amplification Acquired Resistance
A patient who experienced partial response to rociletinib on day 42 of treatment (Supplemental Figure 5A and B in the online version) had disease progression on day 174 due to the emergence of new brain lesions (Supplemental Figure 5B in the online version) but continued to receive rociletinib treatment until day 403, when systemic progression due to peritoneal metastasis occurred (Supplemental Figure 5C in the online version). The patient had detectable EGFR L858R (1.8%), T790M (0.8%), and K860I (1.7%) at screening. At the time of progression, the VAF for L858R had increased to 7.7% and for T790M to 1.5%. Notably, focal MET amplification was observed in plasma collected at the time of progression. While MET amplification was observed in 7.6% (5/66) of the patients with acquired resistance to rociletinib, only 4.5% (3/66) were found to be focal on the basis of the assessment of copy number of other genes sequenced on chromosome 7 (Supplemental Figure 5D in the online version). These results highlight the importance of distinguishing between aneuploidy and focal amplifications because the two may not have comparable biological consequences.
Discussion
This is the largest series of samples that have been profiled from patients with advanced NSCLC treated with a third-generation EGFR TKI using a comprehensive cell-free circulating NGS panel. Although rociletinib was not commercialized, the response rates provide validation of cfDNA NGS measurement of EGFR T790M, and the cohort provides clinical validation of not only T790M but also the initial EGFR driver mutations. Because of tumor heterogeneity, differing sensitivities of cfDNA and tissue NGS assays, and the dynamic nature of ctDNA in patients receiving treatment, response rates are the reference standard for validation of cfDNA-based predictive genomic results.
cfDNA NGS testing was performed to characterize the genomic landscape of patients with T790M-positive NSCLC to better understand the mechanisms of resistance to third-generation EGFR TKIs by using banked rociletinib samples. Somatic alterations were detected in 96% of the pretreatment and 99% of the progression plasma samples. Known EGFR activating mutations (L858R, Ex19Del, or G719X) and the T790M acquired resistance mutation were identified in 93% and 85% of ctDNA-positive pretreatment samples, respectively. These positive percentage agreement values were higher than the reported concordance rates of EGFR mutations in tumor tissue and plasma using different methodologies such as sequencing and amplified refractory mutation system. 31 In a meta-analysis of diagnostic tests, the positive percentage agreement for EGFR mutations in plasma relative to tumor tissue across 12 studies was determined to be 61% (95% CI, 0.50-0.71; n ¼ 1391), 32 while in the ASSESS study, the positive percentage agreement was 46% (95% CI, 38.8-53.4; n ¼ 1162). 33 Given the high agreement in the EGFR mutations detected by tissue and plasma profiling, the clinical activity of rociletinib would be anticipated to be similar in tissue and plasma T790M-positive patients. Indeed, ORR, duration of response, and PFS were comparable in patients who were positive for T790M by tissue or by plasma profiling. Similar findings were also observed in the AURA3 study, where the PFS in osimertinib-treated patients was found to be comparable in tissue and plasma T790M-positive patients. 34 In addition, in a retrospective analysis of the AURA study, plasma T790M-positive patients were shown to have clinical outcomes with osimertinib that were equivalent to T790M-positive patients identified using a tissue-based assay. 35 The ORR and median PFS were almost identical in plasma T790M-positive (ORR, 63%; PFS, 9.7 months) or tumor T790M-positive (ORR, 62%; PFS, 9.7 months) patients. Taken together, these data add to the growing body of evidence demonstrating that plasma EGFR T790M genotyping can be used to noninvasively identify patients who may benefit from third-generation EGFR TKI treatment. Plasma cfDNA NGS testing is also a powerful tool for detecting non-EGFR genomic alterations. Comprehensive molecular profiling of lung adenocarcinoma has previously been assessed in patient populations using predominately untreated tumor samples. [36] [37] [38] In these studies, the frequently mutated genes included TP53, EGFR, STK11, and KRAS. In the present study, cfDNA NGS testing was used to perform comprehensive molecular profiling of NSCLC in patients receiving second-line and later therapy after experiencing disease progression while receiving an EGFR-directed therapy. Consistent with previous studies, significant heterogeneity of alterations was observed, with the most frequent single nucleotide variants outside of EGFR being TP53, RB1, and PIK3CA, and amplifications in CCNE1, MET, and PIK3CA. Likewise, sequencing of progression samples revealed significant heterogeneity with a wide array of somatic variants that either increased or emerged after progression while receiving rociletinib, such that no dominant resistance mechanism was identified in patients whose disease initially responded, then later progressed after receipt of rociletinib. Instead, multiple resistance mechanisms were observed, including EGFR C797S, KRAS/NRAS/HRAS mutations, a NTRK1 fusion, and MET amplification. The co-occurrence of multiple resistance alterations in the same patient implies that targeted monotherapy may not be effective, and that combination therapies will be required to address the genomic clusters that drive resistance, as has been previously posited. 39 EGFR C797S has been reported to be a mechanism of resistance to rociletinib 16 and osimertinib, 15 and was detected in 4.5% (3/66) of patients with acquired resistance to rociletinib in this study. Here, the C797S alteration emerged in 3 patients after long-term drug exposure, suggesting that tumors may have developed C797S under selective pressure from rociletinib treatment as a means to reactivate the EGFR pathway. Detection of EGFR C797S at the time of progression after first-line osimertinib is important because the C797S variant does not drive resistance to the first-generation EGFR TKIs gefitinib and erlotinib; therefore, these agents may serve as potential existing treatment options to these patients.
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Genomic alterations in the genes downstream of EGFR can also reactivate the RAS-MAPK signaling pathway and thereby circumvent the silencing of EGFR signaling by TKIs. In this study, recurrent alterations in genes involved in the RAS-MAPK signaling pathway, including KRAS Q61H, KRAS K117N, HRAS G12R, and NRAS G10R, increased in VAF or emerged at progression in 14% (11/65) of rociletinib-treated patients. Temporal profiling of ctDNA from one patient showed an initial reduction of both the EGFR activating and T790M alterations coincident with the initial clinical response; however, an emergent KRAS Q61H mutation was detected at the time of systemic progression with a VAF of 0.67% on day 191 and increased to 5.7% by day 297. This mutation has been reported to drive resistance to first-and second-generation EGFR TKIs in colorectal and lung adenocarcinoma, 30, 40 and has previously been detected in rociletinib-and osimertinib-treated patients. 16, 18 Nonclinical studies have also demonstrated the transforming potential of the KRAS Q61H mutation on cells, 41 through enhanced GTPase activity and induction of anchorageindependent growth. 42 Thus, our findings suggest that expanded RAS testing of KRAS, NRAS, and HRAS exons 2, 3, and 4 may be important for understanding mechanisms of resistance after disease progression on a third-generation TKI versus limited KRAS exon 2 testing for G12X/G13X mutations. A TPM3-NTRK1 fusion was identified in a patient after disease progression while receiving rociletinib therapy. While TPM3-NTRK1 fusions have predominantly been observed in colorectal cancer, 43, 44 papillary thyroid carcinomas, 45, 46 and glioblastoma, 47 other NTRK fusions such as MPRIP-NTRK1 and CD74-NTRK1 have been observed in lung cancer patients and can result in constitutive TRKA kinase activity. 48 Multiple fusion partners that play oncogenic roles across 19 tumor types have been identified for all 3 NTRK genes, NTRK1, NTRK2, and NTRK3, [49] [50] [51] and the TRKA inhibitors entrectinib and larotrectinib have shown evidence of clinical activity in patients with these alterations. 52, 53 Therapeutics targeting NTRK as a driver alteration may prove useful for resistance alterations involving this same pathway. Copy number amplification of MET has been associated with resistance to EGFR TKIs, and reports of response to MET inhibitors in patients with disease progression while receiving EGFR TKIs highlight the clinical relevance of MET amplification. In a case study, a patient with disease that developed resistance to osimertinib with the emergence of high levels of MET amplification was treated with the MET inhibitor crizotinib, and experienced transient symptomatic benefit. 19 In another study, MET amplification was identified as an adaptive resistance response to osimertinib in 7 out of 23 patients. Among these 7 patients with MET amplification, 3 received combination EGFR/MET TKI therapy, and all 3 had a RECIST partial response. 54 Although MET amplification was observed here in 7.6% (5/66) of the patients with acquired resistance to rociletinib, only 4.5% (3/66) were found to be focal on the basis of the assessment of copy number of other genes sequenced on chromosome 7. The functional consequences of MET aneuploidy are not as well established, highlighting the importance of using cfDNA panels capable of differentiating between focal amplification and aneuploidy to assess therapeutic strategies that address resistance. There are several limitations to our work. At the time of progression, paired tumor tissue was not obtained; therefore, it is not possible to confirm the findings of the plasma-based NGS test in tissue. Nevertheless, a recent blood-to-tissue genotyping concordance study of 543 NSCLC patients found a positive predictive value of > 98% for mutations based on concordance and/or targeted therapy response using this ctDNA NGS method. 55 Another limitation of these studies is that rociletinib is no longer being developed for treatment of patients with EGFR T790M-positive NSCLC. Even though rociletinib and osimertinib are both third-generation TKIs, these drugs are different and have elicited different responses rates in T790M-positive patients. Thus, the mechanisms of resistance may be different between the two TKIs. Given that, the mechanisms of resistance observed in this study need to be confirmed in large studies of osimertinib and other third-generation TKIs approved or in clinical development.
In summary, the data herein regarding blood to tissue concordance for the detection of EGFR driver mutations and EGFR T790M supports the use of cfDNA NGS in patients whose tissue is insufficient or infeasible for genotyping, or who have been under-or incompletely genotyped for all sensitizing or resistance EGFR mutations. Of particular clinical relevance, prediction of response based on cfDNA-detected EGFR T790M was equivalent to tissuedetected EGFR T790M, even at very low mutant allele fractions in plasma. Significant heterogeneity was observed both before and after systemic progression while receiving rociletinib therapy, suggesting that a comprehensive and noninvasive plasma-based NGS or multiplex platform may be useful in understanding genomic alterations and guiding therapies associated with response and resistance to third-generation EGFR TKIs.
Clinical Practice Points
There are no large outcome studies that validate the ability of cfDNA NGS to predict outcomes based on finding EGFR T790M in a noninvasive blood sample. This is the largest series of samples that have been profiled from patients treated with a third-generation EGFR TKI using a comprehensive cfDNA NGS panel. Although rociletinib was not commercialized, the response rates provide validation of cfDNA NGS measurement of EGFR T790M, and the cohort provides clinical validation of not only T790M but also the initial EGFR driver mutations. Because tumor heterogeneity, differing sensitivities of cfDNA and tissue NGS assays, and the dynamic nature of circulating tumor DNA in patients on treatment, response rates are the reference standard for validation of cfDNA-based predictive genomic results. We profiled 77 NSCLC patients with available paired baseline and progression blood samples treated with the third-generation EGFR TKI rociletinib using a broad cfDNA NGS gene panel. We demonstrate the utility of cfDNA NGS to detect EGFR T790M and predict response comparably to tissue-based tests. In addition to the striking genomic heterogeneity observed in baseline samples, we also uncovered a panoply of resistance alterations, including novel events such as emergence of an NTRK1 fusion, and we discuss several longitudinal case studies that shed further light on known resistance mechanisms, such as C797S, as well as the nuances of MET amplification detection.
Because all of the EGFR driver mutations are present in this cohort of tissue-positive EGFR T790M patients, we were able to demonstrate that cfDNA NGS by a 70-gene panel method has sensitivity for EGFR driver and resistance mutations that are superior to a US Food and Drug Administrationeapproved EGFR mutations test for plasma. Because we found a number of acquired resistance mutations after treatment of EGFR T790M patients who experienced disease progression while receiving rociletinib therapy, we predict that understanding resistance to other third-generation EGFR TKIs will require a comprehensive plasma genomic test-that is, a test capable of identifying all 4 types of genomic alterations. We think that fusion and copy number amplifications will arise to drive resistance as well as single nucleotide variants and indels in a multitude of genes. 
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